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Abstract
Background: The ubiquitin-editing cytosolic enzyme A20, the major negative regulator of toll-like receptor (TLR)-
mediated cellular inflammatory responses, has tight genetic linkage with systemic sclerosis (SSc). Because recent
studies implicate endogenous ligand-driven TLR signaling in SSc pathogenesis, we sought to investigate the
regulation, role and mechanism of action of A20 in skin fibroblasts.
Method: A20 expression and the effects of forced A20 expression or siRNA-mediated A20 knockdown on fibrotic
responses induced by transforming growth factor-ß (TGF-ß) were evaluated was evaluated in explanted human skin
fibroblasts. Additionally, A20 regulation by TGF-ß, and by adiponectin, a pleiotropic adipokine with anti-fibrotic activity,
was evaluated.
Results: In normal fibroblasts, TGF-ß induced sustained downregulation of A20, and abrogated its TLR4-dependent
induction. Forced expression of A20 aborted the stimulation of collagen gene expression and myofibroblast
transformation induced by TGF-ß, and disrupted canonical Smad signaling and Smad-dependent transcriptional
responses. Conversely, siRNA-mediated knockdown of A20 enhanced the amplitude of fibrotic responses elicited
by TGF-ß. Adiponectin, previously shown to block TLR-dependent fibrotic responses, elicited rapid and sustained
increase in A20 accumulation in fibroblasts.
Conclusion: These results identify the ubiquitin-editing enzyme A20 as a novel endogenous mechanism for negative
regulation of fibrotic response intensity. Systemic sclerosis-associated genetic variants of A20 that cause impaired A20
expression or function, combined with direct suppression of A20 by TGF-ß within the fibrotic milieu, might play a
significant functional role in persistence of fibrotic responses, while pharmacological augmentation of A20 inhibitory
pathway activity might represent a novel therapeutic strategy.
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Background
Systemic sclerosis (SSc) is characterized by autoimmunity,
vascular injury and tissue fibrosis [1]. Fibroblast activation
resulting in collagen overproduction and myofibroblast
differentiation plays a central role in the development and
progression of fibrosis in the skin and internal organs. The
multifunctional cytokine transforming growth factor-ß
(TGF-ß) is a potent stimulus for fibroblast activation, and
is strongly linked to the pathogenesis of SSc [2]. Although
multiple intracellular pathways have been implicated in
TGF-β-mediated fibrotic responses, cross-regulation
among these networks remain incompletely character-
ized. Moreover, the factors underlying persistence of
pathological inflammation and fibrosis in SSc are largely
unknown. Recent experimental studies and results from
genetic and genomic surveys provide compelling evidence
to link innate immune signaling and toll-like receptor
(TLR) activation to TGF-β activity and persistent fibrotic
response [3].
Toll-like receptors are evolutionary conserved cellular
sensors recognizing both microbial (exogenous) pathogen-
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associated molecular patterns (MAMPs) and endogenous
“damage-associated molecular patterns” (DAMPs) [3, 4].
Deregulated or unchecked TLR activation leads to persist-
ent and unresolving tissue damage. Recent studies provide
evidence for an essential pathogenic role for TLR4 and en-
dogenous TLR ligands in SSc [5]. In order to avoid injury
resulting from aberrant or sustained innate immune re-
sponses, a number of cellular mechanisms have evolved
that negatively regulate TLR signaling [3, 6]. Best studied
of these to date is the ubiquitin-editing enzyme A20
(TNFAIP3), a direct downstream target of TLR signaling,
which is rapidly and transiently induced by lipopolysacchar-
ide (LPS), and negatively regulates both TLR-dependent
and TLR-independent inflammatory responses [7].
Genetic association studies have uncovered tight linkage
of single nucleotide polymorphisms (SNPs) in the A20
locus with susceptibility to autoimmune and inflammatory
diseases, including SSc, in multiple ethnic cohorts [8–10].
Whereas the key role of A20 in modulating TLR4 activity
and target gene expression in immune cells such as mac-
rophages and dendritic cells is now quite well-established,
the regulation, mode of action and importance of A20 in
stromal cells such as fibroblasts remain completely un-
known. Furthermore, the expression and function of A20
in the context of physiologic and pathological matrix re-
modeling have not been explored to date. The genetic
linkage of A20 variants with SSc susceptibility and the
growing recognition of a pathogenic role for TLR signal-
ing in fibrosis and SSc, coupled with the scleroderma-like
skin phenotype described in A20 knockout mice [11]
together suggest a likely important role for A20 in the
pathogenesis of SSc.
In the present studies we demonstrate show that A20 is
detectable in normal skin fibroblasts, and shows sustained
downregulation in response to TGF-β. Forced transient
A20 expression in fibroblasts resulted in suppression of fi-
brotic responses elicited by TGF-ß and TLR4 ligands. These
inhibitory effects of A20 were accompanied by reduced
amplitude of canonical TGF-ß signaling and Smad-
dependent transcriptional responses. These results reveal
an important novel physiologic role for A20 in negatively
regulating the intensity of fibrotic responses in fibroblasts,
which parallels its role in limiting inflammatory responses.
Impaired tissue expression or function of A20 due to SSc-
associated genetic variants, combined with environmental
regulatory influences, might contribute directly to the
development or progression of fibrosis in SSc.
Methods
Cell culture and reagents
Primary cultures of dermal fibroblasts were established by
explantation from neonatal foreskin or adult skin biopsies
as described [12]. Cultures were maintained in Dulbecco’s
Modified Eagle’s medium (DMEM) supplemented with
10 % fetal calf serum (FCS) (Gibco BRL, Grand Island,
NY, USA), 1 % vitamin solutions and 2 mM L-glutamine.
All other tissue culture reagents were from Lonza (Basel,
Switzerland). For experiments, low-passage (3–5) fibro-
blasts were placed in serum-free media containing 0.1 %
bovine serum albumin (BSA) for 24 h prior to addition of
TGF-ß2 (PeproTech, Rocky Hill, NJ, USA), which has
overlapping activity with TGF-ß1 and has been widely
used to study the modulation of fibroblast activity (12,14).
In other experiments, fibroblasts were incubated with re-
combinant human full-length adiponectin (BioVendor,
Karasek, Czech Republic) or ultrapure LPS (InvivoGen,
San Diego, CA, USA).
Isolation and analysis of RNA
Total RNA, isolated from fibroblasts cultures, was
reverse-transcribed to complementary DNA (Cdna) using
qScript cDNA SuperMix (Quanta Bio-Sciences, Gaithers-
burg, MD) and analyzed by real-time qPCR [12, 13]. Prod-
ucts (20 ng) were amplified using SYBR Green PCR
Master Mix (Applied Biosystems, Grand Island, NY, USA)
using an Applied Biosystems 7500 Prism Sequence Detec-
tion System. Results were normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) RNA levels, and fold
change was calculated in the samples [12].
Western analysis
At the end of each experiment, fibroblasts were har-
vested and whole-cell lysates subjected to western ana-
lysis as described [12]. The following antibodies were
used: anti-phospho-Smad2 (Cell Signaling Technology,
Boston, MA, USA), anti-type I collagen (Southern Biotech,
Birmingham, AL, USA), A20 (Santa Cruz, Dallas, TX,
USA), anti-α smooth muscle-actin (αSMA), beta actin and
tubulin (all from Sigma, St. Louis, MO, USA). Proteins
were visualized using ECL reagents (Pierce, Rockford, IL,
USA) and levels were quantitated by determining band in-
tensities normalized to loading controls in each lane using
ImageJ software.
Immunofluorescence confocal cytochemical analysis
Fibroblasts seeded on 8-well Lab-Tek II chamber glass
slides (Nalgene Nunc International, Naperville, IL, USA)
were incubated with TGF-ß (10 ng/ml) or transfected
with A20 (Addgene, Cambridge, MA, USA) in serum-
free DMEM with or without TGF-ß2 (Peprotech, Rocky
Hill, NJ, USA) (10 ng/ml) for up to 24 h. Cells were then
fixed, permeabilized, and incubated with anti-αSMA
(1:100) (Sigma), anti-Smad2/3 (Cell Signaling Technology)
and anti-A20 (1:100) (Santa Cruz) antibodies, followed by
Alexa-fluor-labeled secondary antibodies (Invitrogen). Nu-
clei were identified using 4,6-diamidino-2-phenylindone
(DAPI) and immunofluorescence was evaluated under the
Nikon A1 confocal microscope.
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Transient transfection assays
Fibroblasts at early confluence were transfected with
A20 or empty vector using Lipofectamine®2000 Reagent
(ThermoFisher Scientific, Grand Island, NY, USA) in
parallel [14]. Cultures were incubated in serum-free
media containing 0.1 % BSA for 24 h, followed by TGF-ß2
for a further 24 h. At the end of the experiments, cultures
were harvested and whole-cell lysates were prepared, or fi-
broblasts were fixed and subjected to immunofluores-
cence confocal microscopy. In selected experiments,
fibroblasts were transiently transfected with [SBE]4-luc
plasmid along with Renilla luciferase pRL-TK (Promega)
as control for transfection efficiency. Following a 24-h in-
cubation, whole-cell lysates were prepared and assayed for
their luciferase activity.
Small interfering RNA-mediated knockdown
Fibroblasts were transfected with target-specific small
interfering RNAs (siRNAs) (10 nM) coding for A20 or
scrambled control siRNA (Dharmacon, Lafayette, CO,
USA). At 24 h following transfection, fresh media con-
taining TGF-ß2 (10 ng/ml) were added to the cultures,
and incubations continued for a further 24 h, when total
RNA was isolated for analysis.
Statistical analysis
Data are presented as means ± SD unless otherwise indi-
cated. Differences between two groups were determined
by Student’s t test. A p value <0.05 was considered
statistically significant. Comparisons among three or
more groups were performed using analysis of variance
(ANOVA) followed by Sidak’s correction for multiple
comparisons. Data were analyzed using Graph Pad prism
(Graph Pad Software version 6, Graph Pad Software Inc.,
CA, USA).
Results
A20 is detected in skin fibroblasts and its basal and
inducible expression is suppressed by TGF-ß
While constitutive A20 expression is low in most normal
cell types, A20 was detectable in cultured human fibro-
blasts in the absence of stimulation [7]. In light of the
central role of TGF-ß in modulating pathogenic fibro-
blast responses in SSc, we sought to examine the possi-
bility that it might modulate the expression of A20. To
this end, confluent foreskin fibroblasts were incubated
with TGF-ß. The results demonstrated that TGF-ß treat-
ment induced a dose-dependent and time-dependent de-
crease in A20 gene expression, with maximal inhibition
after 24 h (Fig. 1a and b). Comparable results were seen
when normal adult skin fibroblasts were used (Additional
file 1: Figure S1 and data not shown). To investigate the
cellular mechanisms underlying suppression of A20 by
TGF-ß, we examined the effect of SB43542, a potent and
selective inhibitor of ALK5 receptor-mediated Smad2/3
phosphorylation. The results showed that pretreatment
with ALK5 inhibitor substantially reduced the suppressive
effect of TGF-ß on A20 expression (Fig. 1c), indicating a
key role for canonical Smad signaling in mediating this in-
hibitory effect of TGF-ß on A20.
Expression of A20 is rapidly and transiently induced
by the prototypic TLR4 ligand LPS, and one of the best
characterized roles of A20 is negative regulation of TLR
signaling in an inhibitory feedback loop [6]. We had
shown previously that in normal fibroblasts LPS by itself,
or together with TGF-ß, elicits TLR4-dependent fibrotic
responses [14]. To explore whether LPS induction of
A20 is modulated by TGF-ß, fibroblasts were incubated
with LPS [15], in the presence or absence of TGF-ß.
While LPS enhanced A20 expression as expected,
Fig. 1 Transforming growth factor-ß (TGF-ß) down-regulated basal
A20 expression and prevented its induction. Confluent foreskin
fibroblasts were incubated with TGF-ß2 (10 ng/ml or indicated
concentrations) or ultrapure lipolysaccharide (LPS) (500 ng/ml) for 24 h
or indicated periods. RNA and whole cell lysates were examined by
qPCR (a, b (left panels), c) and western analysis (a, b (right panels), d).
Representative immunoblots (n = 3). Band intensities, normalized for
beta actin or tubulin in each lane are shown below. qPCR results,
normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
are means ± SD of triplicate determinations (n = 3); *p < 0.05
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stimulation was completely abolished by pretreatment of
the cultures with TGF-ß, indicating a dominant inhibi-
tory role for TGF-ß in the regulation of basal and indu-
cible A20 expression (Fig. 1d).
A20 abrogates TGF-ß-induced fibrotic responses in skin
fibroblasts
While A20 has been convincingly implicated in negative
regulation of nuclear factor (NF)-kB-mediated inflam-
matory responses in a variety of cell types [6, 16], its po-
tential impact on modulating fibrotic responses in
fibroblasts has not been explored. We therefore investi-
gated the effect of A20 in transiently transfected human
fibroblasts. While TGF-ß caused marked suppression of
A20, confirming our earlier observations, forced expres-
sion of A20 in these cells attenuated TGF-ß-induced
stimulation of collagen and α-smooth muscle actin
(αSMA) gene expression and myofibroblast differenti-
ation in a dose-dependent manner (Fig. 2a-c). To inves-
tigate the mechanisms underlying these anti-fibrotic
effects, we focused on canonical Smad signaling, which
is recognized as a fundamental pathway driving fibrotic
TGF-ß responses [2]. TGF-ß-induced rapid stimulation
of Smad2 phosphorylation and nuclear localization were
substantially attenuated by ectopic A20 expression in
these fibroblasts (Fig. 3a and b). Moreover, transient
transfection assays indicated attenuated stimulation of
[SBE]4-luc activity in fibroblasts with A20 overexpres-
sion (Fig. 3c). Together, these findings demonstrate a
novel function for A20 as a potent endogenous inhibitor
of Smad-dependent fibrotic responses in fibroblasts.
Ectopic A20 attenuates LPS-induced fibrotic responses
in skin fibroblasts
In light of the previously established profibrotic effects
of TLR4 [14], in complementary experiments we sought
to examine the modulation of these responses by A20.
For this purpose, confluent fibroblasts expressing ectopic
A20 were incubated with LPS and/or TGF-ß. Forced ex-
pression of A20 completely abrogated LPS-induced
stimulation of type I collagen synthesis, COL1A1 and
COL1A2 mRNA expression, and myofibroblast differen-
tiation. These results indicate that A20 blocked TLR4-
dependent fibrotic responses in a manner similar to its
inhibitory effects on TLR4-dependent inflammation
(Fig. 4). Indeed, LPS-induced stimulation of interleukin-
6 (IL-6) was completely abrogated by A20.
Fig. 2 A20 attenuates fibrotic responses elicited by transforming growth factor-ß (TGF-ß). Foreskin fibroblasts transiently transfected with A20 or
empty vector were incubated with TGF-ß2 (10 ng/ml) for 24 h and harvested. RNA, whole cell lysates and media were isolated, and examined by
qPCR (a) and western analysis (b). qPCR results, normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are means ± SD of triplicate
determinations (n = 3). Cgn I Type I collagen, L cell lysates, S secreted. Representative immunoblots (n = 3). Band intensities, normalized for tubulin in
each lane are shown below. c Immunofluorescence confocal microscopy using antibody to αSMA (red). Nuclei identified by 6-diamidino-2-phenylindone
(DAPI) (blue). Bar= 25 μm
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Suppression of fibroblast A20 is associated with
enhanced fibrotic responses
These results suggested that A20 might have a novel
cell-autonomous negative regulatory role in fibrotic re-
sponses. To directly evaluate this possibility, we used an
RNAi approach. Transfection of foreskin fibroblasts with
A20 siRNA caused a substantial reduction in cellular
A20 levels that was accompanied by significantly en-
hanced stimulation of collagen and αSMA gene expres-
sion elicited by TGF-ß (Fig. 5a and c). Moreover, A20
knockdown enhanced both LPS and TGF-ß-induced
stimulation of type I collagen synthesis, COL1A1 and
COL1A2 mRNA expression, and myofibroblast differ-
entiation (Fig. 5b). These results point to a hitherto-
unrecognized cell-autonomous function of A20 in
repressive modulation of fibrotic responses elicited by
TGF-ß or TLR4 ligands.
Adiponectin stimulates the expression of A20
Adipokines secreted from white adipose tissue exert
pleiotropic local and hormonal effects and play key roles
in regulating metabolism, inflammation and tissue repair
(13). Adiponectin is unique among adipokines in that it
is decreased in obese humans and experimental animals
[17, 18]. Adiponectin is secreted from, and targets, not
only adipocytes, but also macrophages and resident stro-
mal cells. Transcriptional profiling in macrophages pre-
viously revealed that one of the top genes upregulated
by adiponectin was A20 [15]. We had shown earlier that
treatment of fibroblasts with adiponectin was associated
with potent anti-fibrotic effects [19]. To investigate
whether adiponectin might have an effect on modulating
the expression of A20 in skin fibroblasts, confluent
monolayers were incubated with recombinant full-length
human adiponectin for various periods. The results
showed that adiponectin treatment in these cells
resulted in rapid upregulation of A20 mRNA, with in-
creased levels as early as 15 minutes (Fig. 6). Increased
A20 protein levels were detected in these cells at 3 h
and were persistently elevated for up to 24 h.
Discussion
Persistent fibrosis in multiple organs, the hallmark of SSc,
is due to excessive extracellular matrix (ECM) secretion
and matrix stiffening driven by metabolically activated
myofibroblasts. While growth factors and morphogens
such as TGF-ß, platelet-derived growth factor (PDGF) and
Wnt ligands have been broadly implicated in triggering
fibroblast activation, the mechanism responsible for main-
taining persistent activation in pathological tissue repair
remain poorly understood [5]. The ubiquitin-editing
enzyme A20 inhibits NF-kB-dependent responses, and al-
terations in its expression or function are implicated in a
variety of chronic inflammatory and malignant conditions
[7]. In light of the multi-ethnic genetic association of sev-
eral SNPs of A20/TNFAIP3 with SSc [10, 20], the present
studies sought to investigate the potential regulatory func-
tion of A20 in modulating fibroblast responses.
Our results show, for the first time, that while A20 is
detectable in unstimulated skin fibroblasts, treatment
with TGF-ß caused marked suppression and prevented
Fig. 3 A20 blocks intracellular canonical transforming growth factor-ß
(TGF-ß)-Smad signaling. Foreskin fibroblasts transiently transfected with
A20 or empty vector were incubated with TGF-ß2 (10 ng/ml) for 24 h.
a Whole cell lysates were examined by western analysis (n = 2).
b Immunofluorescence confocal microscopy using antibody to Smad2/3
(green color). Nuclei identified by 6-diamidino-2-phenylindone (DAPI)
(blue). Bar= 25 μm. c Fibroblasts were transiently co-transfected with
[SBE]4-luc and A20 (50 ng) in absence or presence of TGF-ß2 along with
Renilla luciferase pRL-TK. Following a 24-h incubation, whole-cell lysates
were collected and assayed for their luciferase activity. Results are means
± SD of triplicate determinations (n= 2)
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Fig. 5 Fibrotic responses are negatively regulated by cellular A20. Foreskin fibroblasts were transfected with A20-specific siRNA or scrambled (Scr)
control, followed by incubation with transforming growth factor-ß2 (TGF-ß2) (10 ng/ml), lipopolysaccharide (LPS) (500 ng/ml) or both for 24 h.
a, b mRNA levels were determined by real-time qPCR. Results, normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are means
± SD of triplicate determinations (n = 2). c Western analysis of secreted Type I collagen (Cgn I). ns nonspecific band
Fig. 4 A20 attenuates toll-like receptor 4 (TLR4)-dependent fibrotic responses. Fibroblasts transiently transfected with A20 or empty vector were
incubated with ultrapure lipolysaccharide (LPS) and/or transforming growth factor-ß2 (TGF-ß2) (10 ng/ml). Following a 24-h incubation, RNA
isolated and was examined by qPCR; results, normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are means ± SD of triplicate
determinations (n = 2)
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its induction by LPS. Moreover, A20 exerted a potent
cell-autonomous inhibitory effect on fibrotic gene ex-
pression, and reducing cellular A20 levels was associated
with accentuated fibrotic responses and Smad2/3 activa-
tion. The results indicate that A20 is capable of antagon-
izing intracellular TGF-ß/Smad signaling. In light of the
frequent genetic alterations in the A20 locus in SSc
patients leading to altered A20 expression and/or regula-
tory function, our findings suggest that unchecked TGF-
ß signaling and persistent fibrosis in SSc might result
from impaired A20 in SSc fibroblasts. Conversely,
pharmacologic rescue of A20 in SSc might restore ap-
propriate regulation of fibrotic processes, and could
therefore represent a novel approach to treatment.
A20 is a dual function ubiquitin-editing enzyme with
both deubiquitinase and E3 ubiquitin ligase activities [7].
A20 is most prominently implicated in regulating the dur-
ation and intensity of inflammation, but an expanding
range of biological processes is recognized as modulated
by A20. By inhibiting tumor necrosis factor receptor-
associated factor (TRAF6) ubiquitin ligase, a critical node
in proinflammatory signal transduction, A20 prevents
recruitment of TAK1 and activation of NF-kB [16]. Add-
itionally, A20 also has been shown to inhibit inflammatory
signaling downstream of the IL-1 receptor, TNF receptor,
Nod-like receptor, CD40 and most importantly, TLRs
[21]. The expression of A20 is itself positively regulated by
these inflammatory signals via NF-kB; thus, induction of
A20 constitutes a critical negative feedback loop for NF-
kB signaling.
Recent studies indicate that the deubiquitinase activity
of A20 is not absolutely required for controlling NF-kB
signaling [22]. A20-deficient cells show sustained NF-kB
activation and enhanced inflammatory cytokine produc-
tion in response to TNF and TLR ligands. Mouse models
provide compelling evidence for the critical role of A20
in modulating inflammatory responses. Global deletion of
A20 is associated with premature mortality due to spon-
taneous multi-organ inflammation [11], while partial loss
in haplo-insufficient mice is associated with impaired
tissue regeneration and spontaneous neuroinflammation
[23, 24]. Conditional ablation of A20 in myeloid cells re-
sults in spontaneous arthritis, while ablation of A20 in
dendritic cells causes autoimmune disease with lupus-like
and inflammatory bowel disease features [6]. Mice with
A20 ablation in keratinocytes manifest psoriasis-like epi-
dermal hyperproliferation and disheveled hair in the ab-
sence of inflammation [25]. Several lymphoma types are
associated with somatic mutations and chromosomal de-
letions in the TNFAIP3 locus, and show reduced A20
expression or activity [26]. Genetic studies have linked
germline SNP variants to susceptibility to a variety of
autoimmune and auto-inflammatory diseases along with
SSc [6]. Many of these genetic variants cause reduced ex-
pression or activity of A20.
Recent studies implicate A20 in the pathogenesis of SSc.
Strong association of SSc with a SNP within intron 2
(rs5029939) of A20 was found, particularly in patients with
diffuse cutaneous involvement and fibrosing alveolitis [27].
In a subsequent genome-wide association study (GWAS)
SSc was also associated with the non-synonymous coding
variant rs2230926 [28]. This SNP, the most common A20
coding SNP identified to date in autoimmune diseases,
causes a phenylalanine-to-cysteine change at residue 127,
resulting in a protein with impaired NF-kB inhibitory
activity [29].
In addition to the genetic evidence, further interest in
the A20-SSc link comes from recent studies indicating a
pathogenic role of aberrant TLR signaling in SSc [3]. The
expression of both TLR4 and of its DAMP endogenous li-
gands is markedly enhanced in SSc skin and lung tissue
[12, 30]. Moreover, TLR4 activation on stromal cells elicits
Fig. 6 Adiponectin induces A20 gene expression in fibroblasts. Foreskin fibroblasts were incubated with ultrapure lipolysaccharide (LPS) (500 ng/ml,
30 minutes) (lane 5, left panel) and/or recombinant adiponectin (APN) (10 μg/ml in left panels or as indicated in the right panel) for 0–45 minutes or as
indicated. Left panel, levels of RNA determined by qPCR. Results, normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are means ±
SD of triplicate determinations (n = 2). Right panels, western analysis of whole-cell lysates. Representative immunoblots (n = 2). Band intensities,
normalized for tubulin in each lane are shown below
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sustained fibrotic signaling, and contributes to failure to
resolve experimental fibrosis in mice [14]. The TLR4-
dependent fibrotic response is further amplified in the
presence of TGF-ß [14], suggesting a pathogenic role for
the TLR4 ligand-receptor signaling axis in SSc. Computa-
tional gene network analysis showed that A20 serves as a
central hub for inflammatory-fibrotic networks in skin
lesions in SSc [31]. In view of the consistent genetic as-
sociations of A20 SNPs with disease susceptibility, its
fundamental role in constraining TLR4 signaling, and
the central location of A20 in tissue-specific gene net-
works in SSc, it was of substantial interest to examine
expression, regulation and function of A20 in the con-
text of fibrogenesis.
Expressed in most cell types at low or undetectable
levels, A20 is induced rapidly and transiently by inflam-
matory signals [7]. In autoimmune diseases associated
with A20 SNPs there is reduced NF-kB binding to the
A20 promoter, attenuating A20 expression [32]. Epigen-
etic modifications such as histone acetylation or pro-
moter methylation, might further contribute to reduced
A20 expression or induction, as has been shown in per-
ipheral blood monocytes in systemic lupus erythemato-
sus (SLE) [33] and B cell lymphoma [34]. We found that
treatment of normal fibroblasts with TGF-ß resulted in
time-dependent and dose-dependent repression of A20.
Moreover, in the presence of TGF-ß, LPS treatment of
fibroblasts failed to elicit maximal induction of A20.
While the precise mechanisms underlying negative regu-
lation of A20 by TGF-ß are currently unknown, these
observations provide evidence that excessive local TGF-
ß activity within the fibrotic milieu, a hallmark of SSc
[35], might directly suppress A20. Future studies will be
needed to precisely delineate the reciprocally antagonis-
tic relationship between TGF-ß activity and A20 expres-
sion in SSc.
We found that A20 exerts potent negative effects on
the expression of collagen, αSMA and related genes in-
volved in fibrosis. The inhibitory response involved dis-
ruption of receptor-dependent Smad2/3 activation, the
canonical signaling pathway primarily responsible for
pathological fibroblast activation in fibrosis [5]. In fibro-
blasts overexpressing A20, stimulation with TGF-ß re-
sulted in attenuated Smad2/3 phosphorylation, nuclear
localization, and induction of Smad-dependent transcrip-
tional responses. Therefore, there appears to be a recipro-
cal negative cross-regulatory relationship between TGF-ß
and A20, with TGF-ß suppressing basal and inducible A20
expression, and A20 blocking Smad-dependent fibrotic
responses.
We had shown previously that LPS exerts TLR4-
dependent profibrotic effects mediated, at least in part,
through suppressing miR29, which is an endogenous nega-
tive regulator of fibrotic responses (14). It is noteworthy
that miR29 itself augments A20 expression, due to its com-
petition with the RNA-degrading HuR and prevention of
HuR-mediated transcript decay [36]. Whether A20 modu-
lates the regulation of miR29, and if such regulation might
be potentially implicated in the anti-fibrotic effects of A20,
remain to be investigated. RNAi experiments indicated that
A20 plays a cell-autonomous negative regulatory role in
fibrotic gene expression, and in preventing excessive or
prolonged stimulation of these genes in response to TGF-
ß. It is of interest, in this regard, that mice with global A20
deletion were found to have a scleroderma-like phenotype
with marked thickening of the dermis and disappearance
of the intradermal white adipose tissue [11]. These find-
ings, consistent with unchecked activation of dermal fibro-
blasts, are pathological hallmarks of lesional skin changes
in SSc [1]. In view of these observations, we propose that
enhancing A20 expression or activity in fibroblasts might
be a potential approach to limiting excessive fibrotic sig-
naling elicited by TGF-ß, and perhaps by other fibrotic
stimuli such as Wnt/ß-catenin [37]. In this regard, it is of
great interest that adiponectin, which has both anti-
inflammatory and anti-fibrotic activity [18], elicited sus-
tained A20 induction in fibroblasts. Augmentation of A20
is likely to account for the mitigation by adiponectin of
TLR4-mediated inflammatory and oxidative responses.
While it is currently unknown how adiponectin induces
A20, and whether endogenous A20 contributes to the anti-
fibrotic effects elicited by adiponectin, therapeutic targeting
of the adiponectin-A20 axis using peptide agonists of the
AdipoR1/R2 adiponectin receptors, might be feasible [38].
Taken together, the present findings identify a poten-
tially important novel regulatory role for A20, a perva-
sive genetic risk for SSc susceptibility, in connective
tissue homeostasis and fibrosis. Our results also establish
a potential mechanism for controlling A20 expression by
TGF-ß, which represses A20 in fibroblasts and prevents
A20 induction via TLR4. Moreover, the results indicate
that A20 mitigates fibrotic responses induced by TGF-ß,
and through TLR4 activation, while A20 appears to be
important as a cell-autonomous mechanism for restrain-
ing the amplitude or duration of fibrotic signaling. These
findings implicate A20 as a critical endogenous rheostat
for fibroblast activation and of cutaneous fibrogenesis.
Appropriate induction of A20 in the skin is likely to be
important in maintaining tight spatial and temporal regu-
lation of fibrotic gene responses during wound healing,
and a protective role in limiting excessive scar formation.
These findings are broadly in line with a growing recogni-
tion of A20 as a pleiotropic guardian of tissue homeostasis
by virtue of its combined anti-inflammatory, anti-
apoptotic, anti-oxidant and anti-fibrotic/pro-regenerative
activities [39]. Augmenting A20 expression or function of
A20 within injured tissue microenvironments might limit
ongoing fibrogenic signaling, attenuate fibrosis and
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promote regeneration. Accordingly, pharmacologic agents
that induce A20 expression such as vitamin E (γ-tocotrie-
nol) and MALT inhibitors, along with adiponectin, hold
promise as anti-fibrotic therapies via restoring endogen-
ous A20 expression, particularly when targeted in a tissue-
restricted manner, such as topical application to the skin.
Conclusions
The present findings identify an important novel physio-
logic role for the cytosolic deubiquitinase A20 in fibrosis.
Our results also establish a mechanism for controlling
A20 expression by TGF-ß, which represses A20 in fibro-
blasts and prevents induction via TLR4. Furthermore,
the results indicate that A20 alleviates fibrotic responses
induced by TGF-ß, and through TLR4. These finding
altogether implicate A20 as a critical cell-intrinsic modula-
tor of fibroblast activation and of cutaneous fibrogenesis.
Induction of A20 is likely to serve an important function
in physiologic regulation of cutaneous fibrosis gene re-
sponses during wound healing. Impaired A20 expression
or function due to genetic variants, epigenetic modulation
and/or environmental influences might contribute directly
to the development or progression of fibrosis in SSc, and
represents a promising target for therapy.
Additional file
Additional file 1: Figure S1. TGF-ß suppresses A20 expression in adult
skin fibroblasts. Confluent adult skin fibroblasts were incubated with
TGF-ß2 (10 ng/ml) for indicated time-points. A RNA was examined by
qPCR. Results, normalized with GAPDH, are means ± SD of triplicate
determinations (n = 2). B Western analysis of whole-cell lysates. Representative
immunoblots (n = 2). Band intensities, normalized for beta actin in each lane
are shown below (PDF 50 kb)
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